National Immunobiological Company Information

National Immunobiological Company was established as part of the Rostec state corporation on October 29, 2013 as the organization managing the holding company formation in the immunobiological products development and production. The holding company aims to ensure the independence of the Russian Federation from foreign medicinal drugs (immunobiological drugs and drugs against infectious diseases, in particular) through the development of its own production and scientific expertise. The company carries out development in five major segments of the pharmaceutical market: -vaccines for the National Immunization Schedule; -TB drugs; -blood products; -HIV and hepatitis drugs; -insulin and alternative medications. In particular, the company's development strategy envisages producing up to 100% of the national vaccine needs by 2020 within the National Immunization Schedule and plasma blood factors in volume terms, up to 80% of TB drugs, and 20% of drugs against HIV and hepatitis B and C at the holding facilities. CAREERS National Immunobiological Company employees are a team of professionals, aimed at the realization of the holding's strategic goals. We know that to achieve our main goal of ensuring the drug independence of our country it is necessary to create a team of like-minded people who share the same values and mission and truly love their job. We are a growing company and we set serious and ambitious goals! We are implementing our strategy by providing sustainable development of the pharmaceutical industry of the Russian Federation! We are creating a united team of professionals and like-minded people!